Quantcast

Reportlinker Adds Growth Factors (Blood And Tissue) – A World Report

December 2, 2009

NEW YORK, Dec. 2 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Growth Factors (Blood And Tissue) – A World Report

http://www.reportlinker.com/p0164229/Growth-Factors-Blood-And-Tissue—A-World-Report.html

Age-related conditions such as Alzheimer’s disease, malignancies, trauma and autoimmune disorders necessitate the development of less-invasive and more effective therapies. Growth factors (blood and tissue) have made an indelible mark on the market as a promising and cost-effective therapeutic solution for addressing unmet medical needs. Growth factors have a wide range of opportunities, especially in treating critical conditions such as granulocytopenia, leukemia, aplastic anaemia, bone marrow transplantation, and myelodysplastic syndrome. Additionally, human recombinant technologies have triggered these therapeutic biological products to greater heights.

These and other market data and trends are presented in “Growth Factors ( Blood And Tissue ): A World Report” by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

GROWTH FACTORS (BLOOD AND TISSUE) BMR-1029

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. INTRODUCTION 4

Growth Factors: A Preface 4

Growth Factors: Their Role and Related Applications 4

Growth Factors: Adding a New Dimension 4

Growth Factors: Classification Based on Activity 4

Recent Trends & Developments 5

Recombinant Human Erythropoietin: Gradually Gaining Dominance 5

3. MARKET OVERVIEW 5

EPO – The Lead ‘Factor’ 5

Leading EPO Drugs Worldwide 6

Market Comparison of Erythropoietin-Based Drugs in America

and European Union: Classification Based on Key Parameters 6

Patent Expiries of Major Biopharmaceutical Drugs 7

4. MARKET DYNAMICS 7

Dethroning the Leaders 7

Expiration of Patents Fuels Competition and Sales 8

India – At the Center Stage 8

Side Effects – Still a Concern 8

CDER- A Regulatory Review Authority for Growth Factors 9

5. OUTLOOK 9

Innovative Delivery System Shows Potential for Accelerating

Use of Growth Factors 9

Cytokines – Vital Growth Propellers for the Future of New Drugs 9

Brain Derived Neurotrophic Factor (BDNF) Finds Increased

Application 10

Age-Related Diseases – Their Influence on Effective Therapies 10

Copaxone Finds Novel Applications 10

Mimetic Growth Factors – Exhibiting Promising Potential 11

6. INDUSTRY ISSUES 11

Development of Cost Effective Methods – Need of the Hour 11

Influence of Neurotrophic Factors on Brain Cell Development 12

Combination of Interferons and Ribavirin Develops More Anemia

Cases 12

7. COMPETITIVE TRENDS 13

RegeneRx Focuses on Wound Healing Market 13

DRL Introduces a Program to Propel its Biogenerics Business 13

8. PRODUCT FACTS 13

Blood Growth Factors 14

Erythropoietins 14

Colony Stimulating Factors 14

Interferons 14

Types of Interferons 14

Interleukins 15

Types of Interleukins 15

Tissue Growth Factors 16

Tissue Growth Factors: Classification Based on Key Source and

Principal Activity 16

Growth Factors: Application by Compound and Supplier 17

Growth Factors: Indicated Applications by Site/Course of Action 18

9. RESEARCH AND DEVELOPMENT HIGHLIGHTS 18

Maxygen Updates on Factor VII Program 18

Evaluation of Extended Dosing Schedule of PROCRIT® 19

PROCRIT® – A Better Option 19

Nerve Growth Factor Shows Promising Potential Against Diabetes 19

Cytokines and GM-CSF Found to be Closely Interlinked 20

GM-CSF Enhances Rate of Survival in Neonates 20

rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients 20

rG-CSF- Their Influence on Preterm Infants with Sepsis 21

Serum Macrophage Colony Stimulating Growth Factors Associated

with Thrombocyte and Monocyte 21

Src Pathway Inactivation in Kit Impairs Blood Cell Growth and

Proliferation 22

Cole Eye Institute Offers TIMP-3 Mechanism for Preventing

Abnormal Growth of Blood Vessels 22

Effect of Brain Derived Neurotrophic Factor on Retinal Cells 23

Orcel(TM) Exhibits High Growth Factor for Wound Healing and

Cardiovascular Applications 23

Drug Combination of Macrophage Colony Stimulating Factor Shows

Successful Tolerance Levels 23

Neotrofin(TM) Triggers Neurotrophic Factors 24

G-CSF Shows Capability for Promoting Neutrophil Production 24

Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates

Wound Healing Process 25

Hepatocyte Growth Factors – Exhibiting Dual Role 25

Cortex Pharmaceuticals Ampakines® Promotes Expression of

Neurotrophin 25

Granulocyte Colony Stimulating Factor Finds Application in

Treating Neonates 26

Cerebrolysin Promotes Cognition 26

10. BREAKTHROUGHS – A REVIEW 26

Novel Set of Human Cytokines Unveiled 26

IGFBP-3 and its Potential to Ward Off Gastric Cancer 27

Bone Morphogenic Proteins Show Potential for Musculoskeletal

Regeneration 27

Growth Factors – Their Role in Preventing Heart Stroke 27

Growth Factor Proteins Shows Promising Results for Treating

Cancer 27

Neurotrophic Growth Factor Primarily Responsible for Loss of

Vision 27

Redox-Active Grape Seed Exhibits Favorable Properties for

Dermal Wound Healing 28

Role of Brain-Derived Neurotrophic Factor on Memory 28

Nerve Growth Factor Found to Enhance Barium Current and

Insulin Secretion 28

Lipid Peroxidation May be Associated with Wound Healing 29

Genentech Inc Unveils Molecule for Stimulating Growth of Blood

Vessels 29

Connective Tissue Growth Factor Found to Promote Lung Fibroblast 29

Influence of Insulin-Like Growth Factor on Growth 30

Regeneron Discovers Angiopoietins Targeted at Blood Vessel

Growth and Repair 30

Environment and Insulin-Like Growth Factors Stimulate Risk of

Cancer 30

Cocktail of Neurotrophic Factors Promotes Regeneration of Torn

Nerves 31

Growth Factors Administration to Stimulate Tissue Repair 31

Cytokine – Their Role in Combating Hepatitis C Virus 31

Axokine® Yields Favorable Results Against Obesity 31

Cell Genesys Unveils GDNF Gene Therapy Targeted Against

Parkinson’s Disease 32

11. CORPORATE DEVELOPMENTS 32

Pfizer Inks Exclusive Global Licensing Agreement with Scil

Technology 32

ZGEN Initiates Ph II Trial of Interleukin 21 32

FzioMed Bags Health Canada Approval on Oxiplex® 33

NsGene A/S Implants Encapsulated Cell in Patients 33

Reliance Life Sciences Takes Over Genemedix 33

Fraunhofer Institute Introduces First Interferon Beta 1a to

Treat Multiple Sclerosis 33

Shanghai Wanxing Inks Export Deal for Recombinant Human

Interferon 34

Hemispherx Enters into Distribution Agreement with Armada 34

Bayer Launches US Pharmaceuticals Subsidiary 34

Merck Inks Agreement with Bristol-Myers Squibb and ImClone 35

CoGenesys Signs Global Licensing Agreement with Vegenics 35

InterMune Inks New Supply Deal with Boehringer Ingelheim 35

Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals 36

Cambrex Divests Bioproducts and Biopharma Subsidiaries 36

Dragon Divests EPO Business 36

Caregene and Genzyme Forms Partnership to Develop Cere-120 37

Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric

Patients 37

NsGene to Undertake Phase Ib Clinical Trial of NsG0202 37

Roche Receives European Approval for NeoRecormon 38

Bolder Receives Two U.S. Patents for Hematopoietic Factors 38

Hospira Receives EC Approval on Retacrit 38

RLS to Initiate Clinical Trials of Erythropoietin 38

InterMune Drops Phase III trial of Interferon 38

Chugai to Conduct Additional Trial on Epogin® 39

12. MAJOR PLAYERS 39

Amgen, Inc. (USA) 39

BioMimetic Therapeutics, Inc. (USA) 39

Biopharm GmbH (Germany) 39

Bolder Biotechnology, Inc. (USA) 39

Alseres Pharmaceuticals, Inc. (USA) 40

Ceregene, Inc. (USA) 40

FibroGen, Inc. (USA) 40

FzioMed, Inc. (USA) 40

Insmed, Inc. (USA) 41

Johnson & Johnson (USA) 41

Janssen-Ortho, Inc. (Canada) 41

Lonza Group (Switzerland) 42

Maxygen, Inc. (USA) 42

Merck Serono International S.A. (Switzerland) 42

NsGene A/S (Denmark) 42

PeproTech, Inc. (USA) 43

Rentschler Biotechnologie GmbH (Germany) 43

F. Hoffmann-La Roche Ltd (Switzerland) 43

Chugai Pharmaceutical Co. Ltd. (Japan) 43

Genentech, Inc. (USA) 44

Shantha Biotechnics (India) 44

Scil Proteins GmbH (Germany) 44

Wockhardt Ltd. (India) 44

13. MARKET ANALYTICS 45

14. THE UNITED STATES 53

EPO Market Scenario 53

Key Market Driver for EPO 53

Leading EPO Drugs in the US 53

15. JAPAN 55

Erythropoietin Market: Competitive Scenario 55

Leading EPO Drugs in Japan 55

Market Scenario for Biotech Products 55

Biotech Market Backed by Public Assistance 55

16. EUROPE 57

17. REST OF WORLD 58

An Overview of Indian Market 58

Erythropoietin 58

G-CSF Market 59

Interferon 59

EXHIBITS

Table 1: Global Growth Factors (Blood and Tissue) Market by

Region for the Period 2007-2015 (Sales in US$ Million)

Table 2: Percentage Breakdown of Global Growth Factors (Blood

and Tissue) Market by Region for the Years 2008 & 2012

Table 3: Global Blood Growth Factors Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 4: Percentage Breakdown of Global Blood Growth Factors

Market by Region for the Years 2008 & 2012

Table 5: Global Blood Growth Factors Market by Type for the

Period 2007-2015 (Sales in US$ Million)

Table 6: Percentage Breakdown of Global Blood Growth Factors

Market by Type for the Years 2008 & 2012

Table 7: Global Erythropoietins Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 8: Percentage Breakdown of Global Erythropoietins Market

by Region for the Years 2008 & 2012

Table 9: Global Colony Stimulating Factors Market by Region

for the Period 2007-2015 (Sales in US$ Million)

Table 10: Percentage Breakdown of Global Colony Stimulating

Factors Market by Region for the Years 2008 & 2012

Table 11: Global Interferons Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 12: Percentage Breakdown of Global Interferons Market by

Region for the Years 2008 & 2012

Table 13: Global Interleukins Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 14: Percentage Breakdown of Global Interleukins Market

by Region for the Years 2008 & 2012

Table 15: Global Tissue Growth Factors Market by Region for

the Period 2007-2015 (Sales in US$ Million)

Table 16: Percentage Breakdown of Global Tissue Growth Factors

Market by Region for the Years 2008 & 2012

Table 17: Growth Factors (Blood and Tissue) Market by Type in

the US: 2007-2015 (Sales in US$ Million)

Table 18: Percentage Breakdown of Growth Factors (Blood and

Tissue) Market by Type in the US for the Years 2008 & 2012

Table 19: Growth Factors (Blood and Tissue) Market by Type in

Japan: 2007-2015 (Sales in US$ Million)

Table 20: Percentage Breakdown of Growth Factors (Blood and

Tissue) Market by Type in Japan for the Years 2008 & 2012

Table 21: Growth Factors (Blood and Tissue) Market by Type in

Europe: 2007-2015 (Sales in US$ Million)

Table 22: Percentage Breakdown of Growth Factors (Blood and

Tissue) Market by Type in Europe for the Years 2008 & 2012

Table 23: Growth Factors (Blood and Tissue) Market by Type in

the Rest of World: 2007-2015 (Sales in US$ Million)

Table 24: Percentage Breakdown of Growth Factors (Blood and

Tissue) Market by Type in the Rest of World for the Years 2008

& 2012

COMPANIES PROFILED

To order this report:

Diagnostics Industry: Growth Factors (Blood And Tissue) – A World Report

More Market Research Report


Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus